
The FDA has granted priority review to the new drug application filed for radium-223 dichloride, an investigational compound under review for the treatment of patients with castration-resistant prostate cancer who have bone metastases.

The FDA has granted priority review to the new drug application filed for radium-223 dichloride, an investigational compound under review for the treatment of patients with castration-resistant prostate cancer who have bone metastases.

Nearly a quarter of family physicians order PSA tests without discussing the test with patients, according to a recent study.

This month's round-up of new products includes CIVCO patient drapes, MediSafe Projects' medication alert app, a direct purchase program for Zoladex, and GAMMEX non-latex-sensitive surgical gloves.

New research shows that men with a high risk of bone fracture who are undergoing long-term androgen deprivation therapy (ADT) for prostate cancer have a higher fracture incidence following treatment completion.

More than 3% of prostate biopsies are subject to medical errors or contamination, a recent study found.

In May 2012, the United States Preventive Services Task Force recommended against PSA testing in all men based upon a flawed analysis that overestimated the harms and underestimated the benefits of testing.

This special installment of "Hands On" is presented in a point-counterpoint format, with two leading experts discussing open versus. robot-assisted radical prostatectomy.